ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0587

Barriers to Rheumatologic Care and Antimalarial Refills Among a Cohort of Patients with Systemic Lupus Erythematosus During the COVID-19 Pandemic

Alfredo Aguirre1, Laura Trupin1, Sarah Patterson2, Kimberly DeQuattro2, Patricia Katz3, Cristina Lanata2, Stephanie Rush1, Lindsey Criswell4, Maria Dall'Era5 and Jinoos Yazdany1, 1University of California, San Francisco, San Francisco, CA, 2UCSF, San Francisco, CA, 3University of California, San Francisco, Novato, CA, 4Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA, 5Division of Rheumatology, University of California, San Francisco, CA

Meeting: ACR Convergence 2020

Keywords: Access to care, COVID-19, Health Services Research, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 7, 2020

Title: Health Services Research Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The pandemic of coronavirus disease 19 (COVID-19) has led to widespread disruptions across the spectrum of healthcare. We sought to investigate barriers to medical care, including access to ambulatory rheumatology appointments and routine medications such as antimalarials among patients with systemic lupus erythematosus (SLE) in the San Francisco Bay Area using a diverse, population-based cohort.

Methods: Subjects with SLE in the longitudinal California Lupus Epidemiology Study (CLUES) were administered a structured telephone interview during the COVID-19 pandemic. Participants were asked about SLE disease activity, COVID-19 exposures and infection, demographic factors and patient-reported outcomes. We collected data on access to ambulatory rheumatology appointments. Participants were also asked about difficulties in obtaining timely antimalarial refills since March 2020, encompassing partially filled, delayed or denied refills. Using a multivariable logistic regression model, we investigated demographic (age, female sex, nonwhite race) and disease-related factors (Systemic Lupus Activity Questionnaire, or SLAQ) associated with barriers to timely antimalarial refills.

Results: 202 CLUES cohort members participated in this interview. The mean age was 50 (±13 SD), 91% were female, and 64% reported a nonwhite race/ethnicity. 89 of 99 (90%) participants who tried to access ambulatory rheumatologic care were able to obtain an appointment; 79% of this care was delivered via telephone or video visits. Of the 111 participants who attempted to refill their antimalarial since March 2020, 39 (35%) reported partially filled, delayed or denied refills. Barriers to timely antimalarial refills were not associated with age, female sex, nonwhite race or SLAQ score.

Conclusion: These data suggest that in the San Francisco Bay Area, there were minimal disruptions in access to rheumatologic care for people with SLE, which parallels the high rate of virtual care provided during the first months of the pandemic. However, participants with SLE did report considerable difficulties in obtaining antimalarial refills. This highlights the importance of ensuring an adequate supply and appropriate stewardship of a critical medication for patients with chronic diseases during the COVID-19 pandemic.


Disclosure: A. Aguirre, None; L. Trupin, None; S. Patterson, None; K. DeQuattro, None; P. Katz, None; C. Lanata, None; S. Rush, None; L. Criswell, None; M. Dall'Era, Janssen, 5, AstraZeneca, 5; J. Yazdany, Eli Lilly, 1, Astra Zeneca, 1.

To cite this abstract in AMA style:

Aguirre A, Trupin L, Patterson S, DeQuattro K, Katz P, Lanata C, Rush S, Criswell L, Dall'Era M, Yazdany J. Barriers to Rheumatologic Care and Antimalarial Refills Among a Cohort of Patients with Systemic Lupus Erythematosus During the COVID-19 Pandemic [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/barriers-to-rheumatologic-care-and-antimalarial-refills-among-a-cohort-of-patients-with-systemic-lupus-erythematosus-during-the-covid-19-pandemic/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/barriers-to-rheumatologic-care-and-antimalarial-refills-among-a-cohort-of-patients-with-systemic-lupus-erythematosus-during-the-covid-19-pandemic/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology